Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation strategies in the upfront treatment of multiple myeloma
STaMINA was a phase III trial comparing progression-free survival (PFS) among 758 pts randomized to:
- second autoHCT then lenalidomide (Len) maintenance
- consolidation with Len/bortezomib/ dexamethasone (RVD) followed by Len maintenance
- Len maintenance
Long term outcomes are similar using ITT, but as treated analysis suggested a PFS benefit for tandem autoHCT, driven mainly by pts with high risk MM. Len discontinuation even at 38 mo was associated with inferior PFS.
Clinical trial information: NCT02322320